风湿病患者疫苗犹豫下降,但肌炎患者长期担忧仍存:COVAD调查比较分析
基于COVAD两项国际电子调查(2021年3月至12月及2022年2月至6月),分析18882例(COVAD-1)和7666例(COVAD-2)受访者数据,发现疫苗犹豫从2021年的16.5%降至2022年的5.1%(OR 0.26,95%CI 0.24-0.30,P<0.001),但对长期安全性的担忧增加(OR 3.6,95%CI 2.9-4.6,P<0.01),且特发性炎症性肌病患者对疫苗科学的怀疑及长期安全担忧高于其他自身免疫性风湿病和健康对照。
要点
- 疫苗犹豫从2021年16.5%降至2022年5.1%(OR 0.26,95%CI 0.24-0.30,P<0.001)。
- 对长期安全性的担忧增加(OR 3.6,95%CI 2.9-4.6,P<0.01)。
- 肌炎患者对疫苗科学的怀疑高于其他自身免疫性风湿病(OR 1.8)和健康对照(OR 4)。
核心结论
- 疫苗犹豫从2021年至2022年下降,但肌炎患者尤其是白种人和身体功能较差者仍存在长期安全性担忧。
研究设计与样本
- 两项国际COVAD患者自报电子调查,第一轮于2021年3月至12月发放,第二轮于2022年2月至6月发放(持续进行)。
- 分析COVAD-1的18882例和COVAD-2的7666例受访者数据,涵盖特发性炎症性肌病、其他自身免疫性风湿病、非风湿性自身免疫病和健康对照。
- 采用回归模型分析不同组别中疫苗犹豫的预测因素。
主要发现
- 疫苗犹豫从2021年的16.5%降至2022年的5.1%(OR 0.26,95%CI 0.24-0.30,P<0.001)。
- 对长期安全性的担忧增加(OR 3.6,95%CI 2.9-4.6,P<0.01)。
- 肌炎患者对疫苗科学的怀疑高于其他自身免疫性风湿病患者(OR 1.8,95%CI 1.08-3.2,P=0.023)和健康对照(OR 4,95%CI 1.9-8.1,P<0.001)。
- 肌炎患者对长期安全性的担忧高于其他自身免疫性风湿病患者(OR 1.9,95%CI 1.2-2.9,P=0.001)和健康对照(OR 5.4,95%CI 3-9.6,P<0.001)。
- 白种人更可能犹豫(OR 4.2,95%CI 1.7-10.3),而PROMIS身体健康评分较好者较少犹豫(OR 0.9,95%CI 0.8-0.97)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: COVID-19 vaccines have a favorable safety profile in patients with autoimmune rheumatic diseases (AIRDs) such as idiopathic inflammatory myopathies (IIMs); however, hesitancy continues to persist among these patients. Therefore, we studied the prevalence, predictors and reasons for hesitancy in patients with IIMs, other AIRDs, non-rheumatic autoimmune diseases (nrAIDs) and healthy controls (HCs), using data from the two international COVID-19 Vaccination in Autoimmune Diseases (COVAD) e-surveys. METHODS: The first and second COVAD patient self-reported e-surveys were circulated from March to December 2021, and February to June 2022 (ongoing). We collected data on demographics, comorbidities, COVID-19 infection and vaccination history, reasons for hesitancy, and patient reported outcomes. Predictors of hesitancy were analysed using regression models in different groups. RESULTS: We analysed data from 18 882 (COVAD-1) and 7666 (COVAD-2) respondents. Reassuringly, hesitancy decreased from 2021 (16.5%) to 2022 (5.1%) (OR: 0.26; 95% CI: 0.24, 0.30, P < 0.001). However, concerns/fear over long-term safety had increased (OR: 3.6; 95% CI: 2.9, 4.6, P < 0.01). We noted with concern greater skepticism over vaccine science among patients with IIMs than AIRDs (OR: 1.8; 95% CI: 1.08, 3.2, P = 0.023) and HCs (OR: 4; 95% CI: 1.9, 8.1, P < 0.001), as well as more long-term safety concerns/fear (IIMs vs AIRDs - OR: 1.9; 95% CI: 1.2, 2.9, P = 0.001; IIMs vs HCs - OR: 5.4 95% CI: 3, 9.6, P < 0.001). Caucasians [OR 4.2 (1.7-10.3)] were likely to be more hesitant, while those with better PROMIS physical health score were less hesitant [OR 0.9 (0.8-0.97)]. CONCLUSION: Vaccine hesitancy has decreased from 2021 to 2022, long-term safety concerns remain among patients with IIMs, particularly in Caucasians and those with poor physical function.
引用
- Sen P, R N, Houshmand N, et al. Vaccine hesitancy decreases in rheumatic diseases, long-term concerns remain in myositis: a comparative analysis of the COVAD surveys. Rheumatology (Oxford). 2023. PMID: 36734536. doi:10.1093/rheumatology/kead057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。